View:
Mini BasicThis view is available after user registration.
ShortThis view is available when you buy a license.
StandardThis view is available when you buy a license.
CompleteThis view is available when you buy a license.
Study - CELESTIMO - Mosunetuzumab 30/ Lenalidomide 20, Follicular Lymphoma grade I-IIIa, cycle 2-12
Protocol-ID: 2076 V1.0 (Mini), STUDY - CELESTIMO - MOSU30/LENA20, foll. Lymphoma °I-IIIa, C2-12Indication(s)
- NHL, B-Cell Type, Follicular Grade I-IIIa; ICD-10 C82.9
 | The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician. ©Onkopti. |
Valid since: 31.05.2022